1-20 of 20
Alice T. Shaw
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial

Rafal Dziadziuszko, Solange Peters, Tony Mok, D. Ross Camidge, Shirish M. Gadgeel, Sai-Hong Ignatius Ou, Krzysztof Konopa, Johannes Noé, Malgorzata Nowicka, Walter Bordogna, Peter N. Morcos, Vlatka Smoljanovic, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (9): 1800–1808.
https://doi.org/10.1158/1078-0432.CCR-21-2840
Published: 02 May 2022
View article titled, Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <em>ALK</em>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
Open the PDF for Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <em>ALK</em>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial in another window
Includes: Supplementary data
Journal Articles

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer

Jessica J. Lin, Noura J. Choudhury, Satoshi Yoda, Viola W. Zhu, Ted W. Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Charlotte Lee, Andrew Do, Jennifer Peterson, Kylie Prutisto-Chang, Wafa Malik, Harper G. Hubbeling, Adam Langenbucher, Adam J. Schoenfeld, Christina J. Falcon, Jennifer S. Temel, Lecia V. Sequist, Beow Y. Yeap, Jochen K. Lennerz, Alice T. Shaw, Michael S. Lawrence, Sai-Hong Ignatius Ou, Aaron N. Hata, Alexander Drilon, Justin F. Gainor
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2899–2909.
https://doi.org/10.1158/1078-0432.CCR-21-0032
Published: 15 May 2021
View article titled, Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <em>ROS1</em> Fusion–Positive Lung Cancer
Open the PDF for Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <em>ROS1</em> Fusion–Positive Lung Cancer in another window
Includes: Supplementary data
Journal Articles

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

Kyriakos P. Papadopoulos, Erkut Borazanci, Alice T. Shaw, Ryohei Katayama, Yuki Shimizu, Viola W. Zhu, Thomas Yang Sun, Heather A. Wakelee, Russell Madison, Alexa B. Schrock, Giorgio Senaldi, Naoki Nakao, Hiroyuki Hanzawa, Masaya Tachibana, Takeshi Isoyama, Kenji Nakamaru, Chenhui Deng, Meijing Li, Frank Fan, Qinying Zhao, Yanfei Gao, Takashi Seto, Pasi A. Jänne, Sai-Hong Ignatius Ou
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (18): 4785–4794.
https://doi.org/10.1158/1078-0432.CCR-20-1630
Published: 15 September 2020
View article titled, U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K. Lennerz, Adam Langenbucher, Jessica J. Lin, Marguerite M. Rooney, Kylie Prutisto-Chang, Audris Oh, Nathaniel A. Adams, Beow Y. Yeap, Emily Chin, Andrew Do, Hetal D. Marble, Sara E. Stevens, Subba R. Digumarthy, Ashish Saxena, Rebecca J. Nagy, Cyril H. Benes, Christopher G. Azzoli, Michael S. Lawrence, Justin F. Gainor, Alice T. Shaw, Aaron N. Hata
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2535–2545.
https://doi.org/10.1158/1078-0432.CCR-19-3906
Published: 01 June 2020
View article titled, MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Open the PDF for MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Ibiayi Dagogo-Jack, Marguerite Rooney, Jessica J. Lin, Rebecca J. Nagy, Beow Y. Yeap, Harper Hubbeling, Emily Chin, Jennifer Ackil, Anna F. Farago, Aaron N. Hata, Jochen K. Lennerz, Justin F. Gainor, Richard B. Lanman, Alice T. Shaw
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (22): 6662–6670.
https://doi.org/10.1158/1078-0432.CCR-19-1436
Published: 15 November 2019
View article titled, Treatment with Next-Generation ALK Inhibitors Fuels Plasma <em>ALK</em> Mutation Diversity
Open the PDF for Treatment with Next-Generation ALK Inhibitors Fuels Plasma <em>ALK</em> Mutation Diversity in another window
Includes: Supplementary data
Journal Articles

BRAF Mutation Class and Clinical Outcomes—Response

Ibiayi Dagogo-Jack, Mark M. Awad, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (10): 3189.
https://doi.org/10.1158/1078-0432.CCR-19-0422
Published: 15 May 2019
View article titled, BRAF Mutation Class and Clinical Outcomes—Response
Open the PDF for BRAF Mutation Class and Clinical Outcomes—Response in another window
Journal Articles

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer

Ibiayi Dagogo-Jack, Pablo Martinez, Beow Y. Yeap, Chiara Ambrogio, Lorin A. Ferris, Christine Lydon, Tom Nguyen, Nicholas A. Jessop, A. John Iafrate, Bruce E. Johnson, Jochen K. Lennerz, Alice T. Shaw, Mark M. Awad
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 158–165.
https://doi.org/10.1158/1078-0432.CCR-18-2062
Published: 03 January 2019
View article titled, Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer
Open the PDF for Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Caroline E. McCoach, Collin M. Blakely, Kimberly C. Banks, Benjamin Levy, Ben M. Chue, Victoria M. Raymond, Anh T. Le, Christine E. Lee, Joseph Diaz, Saiama N. Waqar, William T. Purcell, Dara L. Aisner, Kurtis D. Davies, Richard B. Lanman, Alice T. Shaw, Robert C. Doebele
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2758–2770.
https://doi.org/10.1158/1078-0432.CCR-17-2588
Published: 14 June 2018
View article titled, Clinical Utility of Cell-Free DNA for the Detection of <em>ALK</em> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
Open the PDF for Clinical Utility of Cell-Free DNA for the Detection of <em>ALK</em> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist, Xiujun Fu, Christopher G. Azzoli, Zofia Piotrowska, Tiffany G. Huynh, Ling Zhao, Linnea Fulton, Katherine R. Schultz, Emily Howe, Anna F. Farago, Ryan J. Sullivan, James R. Stone, Subba Digumarthy, Teresa Moran, Aaron N. Hata, Yukako Yagi, Beow Y. Yeap, Jeffrey A. Engelman, Mari Mino-Kenudson
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (18): 4585–4593.
https://doi.org/10.1158/1078-0432.CCR-15-3101
Published: 15 September 2016
View article titled, <em>EGFR</em> Mutations and <em>ALK</em> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Open the PDF for <em>EGFR</em> Mutations and <em>ALK</em> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis in another window
Includes: Supplementary data
Journal Articles

Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle

Pasi A. Jänne, Geoffrey Kim, Alice T. Shaw, Rajeshwari Sridhara, Richard Pazdur, Amy E. McKee
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (11): 2613–2617.
https://doi.org/10.1158/1078-0432.CCR-15-2643
Published: 31 May 2016
View article titled, Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle
Open the PDF for Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle in another window
Journal Articles

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

Justin F. Gainor, Daniel S.W. Tan, Tomasso De Pas, Benjamin J. Solomon, Aziah Ahmad, Chiara Lazzari, Filippo de Marinis, Gianluca Spitaleri, Katherine Schultz, Luc Friboulet, Beow Y. Yeap, Jeffrey A. Engelman, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2745–2752.
https://doi.org/10.1158/1078-0432.CCR-14-3009
Published: 14 June 2015
View article titled, Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
Open the PDF for Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib in another window
Includes: Supplementary data
Journal Articles

Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine

Ryohei Katayama, Christine M. Lovly, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (10): 2227–2235.
https://doi.org/10.1158/1078-0432.CCR-14-2791
Published: 14 May 2015
View article titled, Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
Open the PDF for Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine in another window
Journal Articles

Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer

Ryohei Katayama, Yuka Kobayashi, Luc Friboulet, Elizabeth L. Lockerman, Sumie Koike, Alice T. Shaw, Jeffrey A. Engelman, Naoya Fujita
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (1): 166–174.
https://doi.org/10.1158/1078-0432.CCR-14-1385
Published: 05 January 2015
View article titled, Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
Open the PDF for Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer in another window
Includes: Supplementary data
Journal Articles

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

Ryohei Katayama, Luc Friboulet, Sumie Koike, Elizabeth L. Lockerman, Tahsin M. Khan, Justin F. Gainor, A. John Iafrate, Kengo Takeuchi, Makoto Taiji, Yasushi Okuno, Naoya Fujita, Jeffrey A. Engelman, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5686–5696.
https://doi.org/10.1158/1078-0432.CCR-14-1511
Published: 13 November 2014
View article titled, Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Open the PDF for Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib in another window
Includes: Supplementary data
Journal Articles

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies

Christine M. Lovly, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (9): 2249–2256.
https://doi.org/10.1158/1078-0432.CCR-13-1610
Published: 30 April 2014
View article titled, Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies
Open the PDF for Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies in another window
Journal Articles

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

Justin F. Gainor, Anna M. Varghese, Sai-Hong Ignatius Ou, Sheheryar Kabraji, Mark M. Awad, Ryohei Katayama, Amanda Pawlak, Mari Mino-Kenudson, Beow Y. Yeap, Gregory J. Riely, A. John Iafrate, Maria E. Arcila, Marc Ladanyi, Jeffrey A. Engelman, Dora Dias-Santagata, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4273–4281.
https://doi.org/10.1158/1078-0432.CCR-13-0318
Published: 31 July 2013
View article titled, <em>ALK</em> Rearrangements Are Mutually Exclusive with Mutations in <em>EGFR</em> or <em>KRAS</em>: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
Open the PDF for <em>ALK</em> Rearrangements Are Mutually Exclusive with Mutations in <em>EGFR</em> or <em>KRAS</em>: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer in another window
Journal Articles

Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non–Small Cell Lung Cancer?

Adam S. Crystal, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4479–4481.
https://doi.org/10.1158/1078-0432.CCR-12-1952
Published: 30 August 2012
View article titled, Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non–Small Cell Lung Cancer?
Open the PDF for Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non–Small Cell Lung Cancer? in another window
Includes: Supplementary data
Journal Articles

Targeting Anaplastic Lymphoma Kinase in Lung Cancer

Alice T. Shaw, Benjamin Solomon
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2081–2086.
https://doi.org/10.1158/1078-0432.CCR-10-1591
Published: 14 April 2011
View article titled, Targeting Anaplastic Lymphoma Kinase in Lung Cancer
Open the PDF for Targeting Anaplastic Lymphoma Kinase in Lung Cancer in another window
Journal Articles

One Allele's Loss Is Another's Gain: Alterations of NKX2–8 in Non–Small Cell Lung Cancer

Joel W. Neal, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 638–639.
https://doi.org/10.1158/1078-0432.CCR-10-3081
Published: 15 February 2011
View article titled, One Allele's Loss Is Another's Gain: Alterations of <em>NKX2–8</em> in Non–Small Cell Lung Cancer
Open the PDF for One Allele's Loss Is Another's Gain: Alterations of <em>NKX2–8</em> in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Future of Early Detection of Lung Cancer: The Role of Mouse Models

Alice T. Shaw, David G. Kirsch, Tyler Jacks
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (13): 4999s–5003s.
https://doi.org/10.1158/1078-0432.CCR-05-9005
Published: 06 July 2005
View article titled, Future of Early Detection of Lung Cancer: The Role of Mouse Models
Open the PDF for Future of Early Detection of Lung Cancer: The Role of Mouse Models in another window